Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study

Background and Objectives This European Group for Blood and Marrow Transplantation (EBMT) multicentre randomized phase III study was designed to assess the safety and efficacy of CD34+ selection in newly diagnosed myeloma patients undergoing autologous transplantation.Design and Methods One hundred...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jean-Henri Bourhis, Yasmina Bouko, Serge Koscielny, Marleen Bakkus, Hildegard Greinix, Gunter Derigs, Gilles Salles, Walter Feremans, Jane Apperley, Diana Samson, Bo Björkstrand, Dietger Niederwieser, Gösta Gahrton, José-Luis Pico, Hartmut Goldschmidt
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Ferrata Storti Foundation 2007-08-01
coleção:	Haematologica
Acesso em linha:	https://haematologica.org/article/view/4537
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!